For the quarter ending 2025-09-30, BHIC had -$159,984 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | -8,782 | 884,502 |
| Accounts receivable | -326,801 | 289,728 |
| Inventory | 508,981 | 190,200 |
| Deferred revenue | -137,668 | 224,330 |
| Accrued services | -17,814 | 18,507 |
| Accounts payable | -6,471 | 8,410 |
| Prepaid expenses | -12,470 | 42,502 |
| Net cash provided by (used in) operating activities | -340,445 | 613,319 |
| Purchase of intangible assets | 0 | 46,064 |
| Advances from related parties | 1,030,461 | 1,391,635 |
| Repayment to related parties | 850,000 | 1,322,000 |
| Proceeds from the sale of common stock | 0 | 0 |
| Net cash provided by financing activities | 180,461 | 69,635 |
| Net increase in cash | -159,984 | 636,890 |
| Cash and cash equivalents at beginning of period | 662,517 | - |
| Cash and cash equivalents at end of period | 1,139,423 | - |
BioScience Health Innovations, Inc. (BHIC)
BioScience Health Innovations, Inc. (BHIC)